Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Long-term Safety Study of Tadalafil and Macitentan for Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term safety of treatments for two types of lung conditions: pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. These conditions involve high blood pressure in the lungs, which can lead to serious health issues. The study will use a combination of medications, including a drug with the code name JNJ-68150420, which contains the active substances tadalafil and macitentan. Additionally, the study will involve the use of Opsumit, which contains macitentan as its active ingredient.

The purpose of this study is to evaluate the long-term safety of these treatments in participants who have been using them in previous studies. Participants will take the medications in the form of film-coated tablets, which are taken orally. The study will follow participants over a period of time to monitor their health and any potential side effects that may occur while using these treatments.

Throughout the study, participants will be regularly monitored to ensure their safety and to gather information on how the treatments affect their condition. This will help researchers understand the long-term effects of these medications and provide valuable information for future treatment options for people with these lung conditions.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will begin by taking part in a long-term follow-up study. This study is designed to monitor the safety of the treatments being used for pulmonary hypertension.

    The participant will be required to sign an informed consent form, indicating an understanding of the study's purpose and procedures.

  2. Step 2

    Medication administration

    Participants will continue taking the medications they were using in the previous study. These include macitentan and a fixed-dose combination of macitentan 10 mg and tadalafil 40 mg, both administered orally.

    The medication is provided in the form of film-coated tablets.

  3. Step 3

    Monitoring and follow-up

    Participants will be monitored for any adverse effects that may arise from the treatment. This includes tracking any new symptoms or changes in health status.

    Regular follow-up appointments will be scheduled to assess the participant's response to the treatment and to ensure their safety.

  4. Step 4

    Safety assessments

    The study will evaluate the frequency of any adverse events, including serious adverse events or any that lead to discontinuation of the treatment.

    Participants will be required to undergo regular health assessments to ensure the continued safety of the treatment.

  5. Step 5

    End of study

    The study is expected to conclude by December 13, 2027. Participants will be informed of the study's outcomes and any necessary follow-up actions at this time.

Who can join the trial?

9 criteria

  • The participant must sign an informed consent form, which is a document that shows they understand the study and agree to take part. If the participant is under 18, their parent(s) must sign, and the child must also agree if they are old enough to understand.
  • The participant must have been treated with the study medication (macitentan, selexipag, or a fixed-dose combination of macitentan and tadalafil) at the end of a previous related study.
  • The participant must have completed the previous study related to the current study.
  • No other way to access the study medication or a similar approved treatment should be available to the participant.
  • The participant should still benefit from continuing the study medication.
  • For children, the participant must be at least 2 years old.
  • A female participant who can have children must have a negative pregnancy test before starting the study medication.
  • The female participant must agree to take a pregnancy test every month until the end of the study's safety follow-up period.
  • The female participant must agree to use birth control methods as defined in the study guidelines until 30 days after the last dose of the study medication.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Study Intervention: This refers to the specific treatment or medication being tested in the clinical trial for pulmonary hypertension. The study aims to observe the long-term safety of this intervention in participants who have been using it in previous related studies. The exact name of the medication or therapy is not provided, but it is the main focus of the trial to ensure its safety over an extended period.

What is already known about the treatment

Macitentan – This medication is administered orally in tablet form and is primarily used to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. It is currently well-documented in medical literature and is approved for use in managing these conditions. Macitentan works by blocking endothelin receptors, which helps to relax blood vessels and reduce blood pressure in the lungs. It is classified as an endothelin receptor antagonist.

Investigated diseases

  • Pulmonary Arterial Hypertension

    This is a condition where the blood pressure in the arteries of the lungs is higher than normal. It occurs when the small arteries in the lungs become narrowed or blocked, making it harder for blood to flow through them. As a result, the heart has to work harder to pump blood through these arteries. Over time, this increased workload can lead to the weakening of the heart muscle. Symptoms often include shortness of breath, fatigue, and dizziness. The disease can progress gradually, with symptoms worsening over time.

  • Chronic Thromboembolic Pulmonary Hypertension

    This condition arises when blood clots obstruct the blood vessels in the lungs, leading to increased blood pressure in these vessels. It is a form of pulmonary hypertension that persists after a blood clot in the lung, known as a pulmonary embolism, has resolved. The obstruction of blood flow causes the heart to work harder to push blood through the lungs. Over time, this can lead to heart strain and reduced oxygen levels in the blood. Symptoms may include shortness of breath, fatigue, and chest pain. The condition can develop slowly, with symptoms becoming more pronounced as the disease progresses.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506791-27-00Protocol codeNOPRODPAPUH3001Estimated enrolment156 patientsSponsorActelion Pharmaceuticals Ltd.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.